Reclassifying Treatment for High-Risk Metabolic Dysfunction-Associated Steatotic Liver Disease Using Endohepatology A Prospective Multicenter Observational Study
Led by University Hospital Muenster · Updated on 2026-10-20
500
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how endohepatology may change treatment decisions for adults at high risk of metabolic dysfunction-associated steatotic liver disease MASLD. This prospective observational study focuses on comparing treatment indications based on non-invasive tests versus advanced endohepatology assessments including liver biopsy and portal pressure measurements. The study aims to understand if these endohepatology methods provide important additional information for managing MASLD and related liver conditions.
Participants first undergo clinical assessments, blood tests, abdominal ultrasound, and various non-invasive liver stiffness and fibrosis tests. Those with abnormal or unclear results receive a single-session endohepatology evaluation involving upper gastrointestinal endoscopy with EUS-guided shear-wave elastography, portal pressure measurement, and liver biopsy. Treatment indications based on these detailed assessments are compared with the initial non-invasive results. Follow-up continues for 24 months following enrollment.
During the study, participants have several assessments including laboratory tests, imaging, and biopsies as applicable and consented. Samples like blood, saliva, stool, and tissue biopsies may be collected for translational research. Researchers measure changes in treatment indications after endohepatology, the presence of liver fibrosis and portal hypertension, and monitor for adverse events and liver-related outcomes over two years. Safety is closely followed, especially after invasive procedures, to ensure participant well-being throughout the study.
CONDITIONS
Brief Title
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
Research Team
M
Michael Prof. Dr. Praktiknjo, MD PhD
D
Dominik Dr. van de Loo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Previous organ transplantation or transjugular intrahepatic portosystemic shunt (TIPS)
Current resmetirom therapy
Decompensated cirrhosis
Vascular liver disease
Contraindication to endoscopy, sedation, or liver biopsy
Pregnancy or breastfeeding
Inability to provide informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Non-invasive Assessment and Follow-up
Duration - Up to 24 months
Participants undergo clinical assessments, laboratory tests, abdominal ultrasound, and various non-invasive liver tests. Those with low-risk and reliable results continue with non-invasive follow-up.
Scheduled follow-up visits based on risk group
Endohepatology Assessment
Duration - Single session within 4 to 8 weeks after screening
Participants with abnormal or unreliable non-invasive findings receive a single-session endohepatology evaluation including upper gastrointestinal endoscopy, EUS-guided elastography, portal pressure measurement, and liver biopsy within 4 to 8 weeks after screening.
1 endohepatology visit
Long-term Follow-up
Duration - 24 months
Participants are monitored for liver health outcomes, adverse events, and treatment changes for 24 months after enrollment.
Periodic visits during follow-up
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Using 3D Magnetic Resonance Elastography to Assess Cirrhosis, Advanced Chronic Liver Disease, and Portal Hypertension
A Prospective Multicenter Study to Develop a Non-Invasive Risk Stratification Method
Non-invasive 4D-Flow MRI to Assess Portal Hypertension and Predict Outcomes After TIPS in Cirrhosis
Pilot Study of an AI Chatbot for Reducing Alcohol Use in Adults with Metabolic Alcohol-Related Liver Disease
Randomized Trial of Retatrutide and Tirzepatide in Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease to Prevent Major Liver Outcomes
Phase 3 Randomized, Double-Blind Study of Efimosfermin Alfa Injection Versus Placebo in Adults With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis
Evaluating ECC4703 and ECC0509, Alone and Combined, for Liver Fat Reduction in Adults With Metabolic Dysfunction-associated Steatohepatitis
Phase 2 Study of Efimosfermin Alfa Treatment in Adults With Biopsy-Confirmed Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Pharmacokinetics of INI-822 in Healthy Adults and Participants With Metabolic Dysfunction-Associated Steatohepatitis
SEC-HOPE Observational Study of Secukinumab Retention in Adults with Plaque Psoriasis and MASLD in Spain
Study of Splenectomy Effects on Surgery and Recovery in Adults with Acute Necrotizing Pancreatitis and Portal Hypertension
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study.
Emma Vanderschueren, Wim Laleman, Lawrence Bonne...
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study.